C4 Therapeutics to present new biomarker data for cemsidomide plus dexamethasone
C4 Therapeutics said it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd IMS Annual Meeting.
WATERTOWN, Mass., Sept.
03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) NASDAQ:CCCC, a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combi…